Advances in malignant mesothelioma therapy: targeting EphA2 - a novel approach (original) (raw)
Related papers
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach
American journal of cancer research, 2012
Eighth International Mesothelioma Interest Group
Oncogene, 2007
Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells
Cancer, 2006
Anti-Cancer Drugs, 2000
The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
Journal of Thoracic Oncology, 2009
Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma
American journal of cancer research, 2011
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma
Carcinogenesis, 2002
Clinical aspects of malignant mesothelioma in Australia
Australian and New Zealand Journal of Medicine, 1993
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge
Cancer Immunology, Immunotherapy, 2018
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
Scientific Reports, 2016
Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
PLoS ONE, 2012
Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
Oncotarget, 2017
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Journal of Thoracic Oncology, 2018
Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy
Cancer Gene Therapy, 2005
Malignant Mesothelioma In Situ: Clinical and Pathologic Implications
Journal of Thoracic Oncology, 2020
Archives of Pathology & Laboratory Medicine, 2013
Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance
2005
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Cancer Immunology, Immunotherapy, 2014
The American Journal of Pathology, 2009
A Turning Point for Mesothelioma Therapy
JCO Oncology Practice, 2021
Mesothelioma treatment: Are we on target? A review
Journal of Advanced Research, 2014
Emerging Drug Therapies for Mesothelioma
Mesothelioma, 2020
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
Expert opinion on investigational drugs, 2017
State of the Art: Concise Review Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018
Metachronous malignant mesothelioma and pulmonary adenocarcinoma
Turkish Journal of Pathology, 2013
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
PLoS ONE, 2014
A Glimpse in the Future of Malignant Mesothelioma Treatment
Frontiers in Pharmacology
Malignant mesothelioma in situ: morphologic features and clinical outcome
Modern Pathology, 2019
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects
Frontiers in Oncology
Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!
Pathology Research and Practice, 2022
Lung Cancer, 2018
The hippo pathway provides novel insights into lung cancer and mesothelioma treatment
Journal of Cancer Research and Clinical Oncology, 2018
The α folate receptor is highly activated in malignant pleural mesothelioma
The Journal of Thoracic and Cardiovascular Surgery, 2001
Ras Pathway Activation in Malignant Mesothelioma
Journal of Thoracic Oncology, 2007